Teriparatide vs Ac-SDKP

Head-to-head comparison of Teriparatide (Parathyroid Hormone (1-34)) and Ac-SDKP (N-Acetyl-Seryl-Aspartyl-Lysyl-Proline) — benefits, dosing, side effects, research data, and where to buy.

Research Score

PropertyTeriparatideAc-SDKP
CategoryRecovery & HealingRecovery & Healing
Full NameParathyroid Hormone (1-34)N-Acetyl-Seryl-Aspartyl-Lysyl-Proline
Molecular Weight4117 Da432.4 Da
Half-Lifeabout 1 hourminutes
Amino Acids344
Typical Dose20 mcg daily10–100 µg/kg/day in pre-clinical studies
RouteSubcutaneousSubcutaneous
Purity≥98%≥98%
Studies Count1200180
Research StatusClinicalPre-clinical

Teriparatide Benefits

  • ✓stimulates bone formation
  • ✓supports fracture union
  • ✓improves bone mineral density
  • ✓may aid bone remodeling

Ac-SDKP Benefits

  • ✓anti-inflammatory tissue remodeling
  • ✓fibroblast modulation
  • ✓microvascular protection
  • ✓faster regenerative signaling

Teriparatide Dosing

20 mcg subcutaneous daily|intermittent anabolic exposure|monitor calcium and vitamin D status

Ac-SDKP Dosing

Research-only systemic microdoses|short daily dosing in animal models|route varies by study

Teriparatide Side Effects

  • ⚠hypercalcemia
  • ⚠nausea
  • ⚠dizziness

Ac-SDKP Side Effects

  • ⚠GI upset
  • ⚠hypotension at high exposure
  • ⚠unknown long-term safety

Research Overview

Teriparatide

Teriparatide has extensive clinical literature showing anabolic effects on bone and investigational use in delayed unions and nonunions. It is one of the best-studied peptide-based options for skeletal recovery.

Ac-SDKP

Ac-SDKP has literature in tissue remodeling, angiogenesis, and organ repair models. Its strongest evidence is pre-clinical, where it modulates inflammation and fibrosis during healing.

Ready to buy?

Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.

Common Stacking Partners

Teriparatide stacks with:

Vitamin D3CalciumCollagen peptides

Ac-SDKP stacks with:

EGFFGF2
bone-healingfracture-repairosteoanabolicpeptidetetrapeptidetissue-remodelinganti-fibrotic